about
Nolz1 promotes striatal neurogenesis through the regulation of retinoic acid signalingCystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Vesicular glutamate transporter 3 (VGLUT3) identifies spatially segregated excitatory terminals in the rat substantia nigraIncreased opioid dependence in a mouse model of panic disorder.Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area.Helios expression coordinates the development of a subset of striatopallidal medium spiny neuronsNeuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.Fast and efficient neural conversion of human hematopoietic cellsHelios transcription factor expression depends on Gsx2 and Dlx1&2 function in developing striatal matrix neurons.Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease.A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtinMyeloid C/EBPβ deficiency reshapes microglial gene expression and is protective in experimental autoimmune encephalomyelitis.Forced cell cycle exit and modulation of GABAA, CREB, and GSK3β signaling promote functional maturation of induced pluripotent stem cell-derived neurons.Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells.Interplay of leukemia inhibitory factor and retinoic acid on neural differentiation of mouse embryonic stem cells.PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.Novel cryopreservation method for dissociated human embryonic stem cells in the presence of a ROCK inhibitor.Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism.In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules.Induction of GABAergic phenotype in a neural stem cell line for transplantation in an excitotoxic model of Huntington's disease.Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum.Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease.Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes.Cryopreservation of dissociated human embryonic stem cells in the presence of ROCK inhibitor.Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease.Quantitative high-throughput gene expression profiling of human striatal development to screen stem cell-derived medium spiny neurons.Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism.Distinct roles of the Y1 and Y2 receptors on neuropeptide Y-induced sensitization to sedation.TrkB and TrkC are differentially regulated by excitotoxicity during development of the basal ganglia.Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons.Disruption of EphA/ephrin-a signaling in the nigrostriatal system reduces dopaminergic innervation and dissociates behavioral responses to amphetamine and cocaine.Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration.Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.
P50
Q24297178-9A391014-D7D6-4040-BD95-542362438684Q24548047-4C100BC7-80B0-44AD-8F76-13537E107F64Q28572701-48B4E17B-FA21-4886-9B48-4D9FF20283F9Q30493463-29F03315-2FE1-4950-994C-4A1D2E725958Q31813509-46A2449C-43F3-4A80-891D-1205C36C2BB9Q33588405-D30DD782-C3B5-47A0-A996-32B2E5CBDD78Q34657624-3AEF7C93-EE88-4F19-B451-B0F961062986Q34684538-381FE35B-B48B-43EF-9B6F-EBF0821F3335Q36138530-C78AEC12-2118-433B-B5CE-E193A4B1A183Q36410154-181DF7A8-EA94-492F-AECC-26954954CA29Q36549749-754084F8-AA71-4E09-AF35-520F483C8961Q37153804-5EA3FE56-CCD4-4E88-B9DA-D19D78CB00E2Q37708277-E9E6128C-DCEF-48E1-9306-0673A7766A4AQ38807798-795411F5-6313-4E33-B037-BE0FC9D6294BQ39767290-FF4261BB-704A-4D1D-B28C-45038E483460Q39789125-45DCD71C-5561-4B4A-B55B-931707C44AB2Q39800916-F08EF016-35D3-4A55-B0C0-9A6639197692Q39932912-E6B3A0D2-0320-4E0C-A397-012C196059B1Q39948812-4A82BDCF-D51B-42F6-96BD-6507B17B573CQ40199654-2933FC73-55DA-49E0-AB10-B7830878D115Q40212781-04DE8298-9488-4A21-A6A4-C55963405D05Q40506280-9418DB88-7DA1-4428-B0FE-1AB9C76AEA19Q40519742-CBAFB734-813E-442D-A6F3-C90084F4C18DQ40741337-9902D283-11CA-469B-B630-6E7EE8EEBB35Q40776566-B16EB11C-9826-4D50-970A-42D964560861Q40873179-97FF9227-DDE3-4BBF-8904-BE0A34976F57Q40942115-5DB183E1-A435-4C38-B4B8-93DE361A9235Q41610148-2375152A-395B-4ED0-8824-ECCD82F98BA7Q41964090-78D6F02F-5E21-44B7-B929-50C5795C6540Q42956133-8F503124-40FA-4F0C-8910-5930B0C10D70Q42966819-AB52B25C-CD02-4231-868F-7B3EA4C41695Q43674629-B5BAB754-ABD0-44E3-BA24-9D2CCCB37503Q43752317-03062F00-4B3F-41AC-A52E-3113182C16B5Q43804607-44D25814-7305-4993-93F5-5F8765FDAB8BQ43899949-2EFE7490-8AC3-443E-9265-76D2E87639DCQ44963984-0D0958D5-9A85-42CF-9536-3366B3F69734Q45288581-CFB05A7E-1FA5-4F20-B204-C03E2ED64FAEQ45292466-1637CBEC-4D5A-4563-81E4-DFB58C6A6C13Q45297067-861FE4D3-AABE-4F25-A460-89EB2F06D5A9Q45297386-4F297ED1-04E7-41EF-A0F8-FB8848AFE752
P50
description
Spaans onderzoeker
@nl
hulumtues
@sq
researcher
@en
taighdeoir
@ga
հետազոտող
@hy
name
Josep M. Canals
@ast
Josep M. Canals
@en
Josep M. Canals
@es
Josep M. Canals
@ga
Josep M. Canals
@nl
Josep M. Canals
@sl
type
label
Josep M. Canals
@ast
Josep M. Canals
@en
Josep M. Canals
@es
Josep M. Canals
@ga
Josep M. Canals
@nl
Josep M. Canals
@sl
prefLabel
Josep M. Canals
@ast
Josep M. Canals
@en
Josep M. Canals
@es
Josep M. Canals
@ga
Josep M. Canals
@nl
Josep M. Canals
@sl
P1053
M-3846-2014
P106
P1153
35585802400
P21
P27
P31
P3829
P496
0000-0001-6829-7670